Articles by William Looney

2013 Dealmakers Outlook

Apr 1, 2013
By: William Looney

Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead.

The conversation thread that binds this month's Pharm Exec is building communities—when the harsh economics of market change suddenly discounts the familiar, then the best way to move up is to reach out.

Right Board for the Brand

Mar 1, 2013
By: William Looney

Pharm Exec's 35-member Editorial Advisory Board met last month to discuss a range of topics, including the influence of other business sectors on pharma's global strategy.

Oncology: Pathways to Progress

Feb 1, 2013
By: William Looney

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.

In Cancer, Process Drives Progress

Feb 1, 2013
By: William Looney

Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.

Industry Forecast 2013

Jan 25, 2013
By: William Looney

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.

The Long Swim—Upstream

Jan 1, 2013
By: William Looney

2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise—as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.

The Permanent Campaign

Jan 1, 2013
By: William Looney

Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.